Need information?
CONTACT US
You are here
Sepsis Management
Sepsis is now defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection1. This serious condition incurs long hospital stays, and high morbidity and mortality. The WHO has recognized sepsis as a Global Health Priority2, and the Surviving Sepsis Campaign’s latest guidelines3 (2016) offer very clear strategies for better patient outcomes.
When time is critical, you need accurate information – and you need it fast. bioMérieux is your partner along the sepsis management pathway, bringing you rapid and reliable results to support clinical decisions for better patient care.
Add to your selection
Do you need more information?
Sepsis: every minute counts
|
Treat sepsis early – save lives “Rapid initiation of simple, timely interventions, including antimicrobials and intravenous fluids, can reduce the risk of death by half. Patients with suspected sepsis should be referred immediately to an appropriate facility. Early sepsis treatment is cost effective, and reduces the number of hospital and critical care bed days for patients” |
Sepsis is a complex inflammatory process that is largely under-recognized as a major cause of morbidity and mortality worldwide. Yet, with an estimated 30 million cases each year worldwide, sepsis causes 1 death every 3-4 seconds4. It is the leading cause of death from infection around the world, despite advances in modern medicine like vaccines, antibiotics, and acute care4.
Sepsis is caused by an acute response of the body’s immune system to a severe infection, often resulting in damage to the patient’s own tissues and organs.. It can lead to shock, multiple organ failure, and death, especially if it is not recognized early and treated promptly. Long-term effects for sepsis survivors include permanent organ damage, as well as physical and cognitive disability3,4.
Despite medical advances, the number of sepsis cases continues to rise rapidly3,5,6. Along with rising incidence there are rising costs: in the US, hospital treatment accounts for nearly $24 billion per year5; in Germany, costs for treating a typical case are reported to have more than doubled in the last decade7.
The “Golden hour”
Early diagnosis and appropriate treatment make a critical difference when it comes to improving sepsis patient outcomes. Indeed, chances of survival go down drastically the longer initiation of treatment is delayed. If a patient receives antimicrobial therapy within the first hour of diagnosis, chances of survival are close to 80%; this goes down by 7.6% for every hour after8. Yet, if a patient initially receives inappropriate antimicrobial treatment, they are five times less likely to survive9.
A Global Health Priority
In 2017, the World Health Organization (WHO) adopted a resolution recognizing sepsis as a Global Health Priority and is focused on improving the prevention, diagnosis, and management of sepsis2
Updated guidelines: protocols for efficient response
The Surviving Sepsis Campaign, a joint collaboration of the Society of Critical Care Medicine and the European Society of Intensive Care Medicine, published the fourth edition of its guidelines in 2016: Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 20163. Based on a wide body of research, these guidelines offer key recommendations to ensure best patient outcomes.
The Surviving Sepsis recommendations start with initial resuscitation and carry through 10 recommendations of care and monitoring, along with special considerations for pediatrics10. The microbiology laboratory plays a vital role throughout the sepsis management pathway, in particular for some of the most critical recommendations: routine patient screening, diagnosis and antimicrobial therapy.
Some key Surviving Sepsis recommendations (summarized)*
*Full guidelines available at: http://www.sccm.org/Documents/SSC-Guidelines.pdf |
Clinicians depend upon rapid and reliable diagnostics for clinical decision-making every step of the way. So how can in vitro diagnostics help you meet that challenge?
Early patient management in sepsis
When a patient presents with suspected sepsis, appropriate cultures (blood samples or samples from site of infection) should be obtained within the first hour, before starting antimicrobial therapy. Biomarkers such as procalcitonin (PCT) may also rapidly (20 minutes) give answers to support diagnosis or prognosis. To initiate appropriate therapy as early as possible, it is important not only to identify the pathogen, but also to test for resistance to antimicrobials. Antibiotic treatment effectiveness must be monitored continually. Finally, epidemiological surveillance and antimicrobial profiling help determine local epidemiology and hospital antimicrobial policies.
At bioMérieux, we understand that each of these steps is not an isolated activity but rather a continuum of care that involves close collaboration between the microbiology lab and the clinical care setting. That’s why we’ve developed a global patient-centric solution for sepsis to support you all the way along the continuum. We understand that actionable laboratory results lead to informed clinical decisions and improved patient outcomes.
|
Surviving Sepsis recommendations |
bioMérieux supports your needs |
|
|
DIAGNOSIS
|
Blood cultures |
|
|
Blood culture identification |
 |
|
|
Site specific cultures Conventional culture media |
|
|
|
Microbial identification / Antimicrobial resistance testing |
|
|
|
Procalcitonin (PCT) immunoassay |
|
|
|
ANTIMICROBIAL THERAPY
|
Antimicrobial resistance profiles/Rapid result reporting VITEK® 2 / Advanced Expert System™ |
 |
A partner you can count on for sepsis management
|
By microbiologists, for microbiologists bioMérieux solutions are designed by microbiologists, for microbiologists. With more than 50 years’ experience working with laboratories, we’ve been by your side throughout the evolution of challenges facing labs around the world, including the growing threat of sepsis. |
bioMérieux is acutely aware of the challenges the microbiology lab faces daily in the fight against sepsis and the need for leading-edge diagnostics. Along with our continual innovation in rapid diagnostic solutions and tests, we are also a sponsor of World Sepsis Day.
Like you, providing the best possible patient care is at the heart of our concerns. So you can count on us to be by your side, facing the sepsis management challenge.
Not all of the products are FDA cleared.
FDA cleared products may not be cleared for all indications mentioned on this site.
Product claims may differ from country to country on regulations and approvals. Please contact your country representative for further details.
References:
1. Singer et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810
2. Reinhart et. Al, Recognizing Sepsis as a Global Health Priority- A WHO resolution. N Engl J Med 2017; 377:414-417August 3, 2017
3. Rhodes A., et al. “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016”. Intensive Care Med (2017) 43:304–377
4. WSD fact sheet 2017/www.world-sepsis-day.org
5. Torio, Celesten, et. al. (2013). National Inpatient Hospital Costs: The Most Expense Conditions by Payer, 2013. Statistical brief #204. May 2016. www.hcup-us.ahrq/reports/statbriefs
6. International Organizations Declare Sepsis a Medical Emergency. Issued by an expert panel representing 20 adult and pediatric intensive care societies, October 4th 2010. 2010: Press release. http://www.prnewswire.com/news-releases/international-organizations-decl...
7. Vincent JL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med, 34:344-353, 2006.
8. Kumar, A, et. al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96.
9. Kumar, A, et. al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest. 2009 Nov;136(5):1237-48.
Pioneering diagnostics